These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36812897)

  • 1. Patient-Reported Outcomes in Young Adults with Myeloproliferative Neoplasms.
    Bao M; Zhang M; Shi H; Liu X; Duan M; Zhuang J; Du X; Qin L; Hui W; Liang R; Wang M; Chen Y; Li D; Yang W; Tang G; Zhang W; Kuang X; Su W; Han Y; Chen L; Xu J; Liu Z; Huang J; Zhao C; Tong H; Hu J; Chen C; Chen X; Xiao Z; Jiang Q
    Acta Haematol; 2023; 146(4):293-306. PubMed ID: 36812897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical and genetic characteristics of young patients with myeloproliferative neoplasms].
    Zhang MY; Bao M; Shi DY; Shi HX; Liu XL; Xu N; Duan MH; Zhuang JL; Du X; Qin L; Hui WH; Liang R; Wang MF; Chen Y; Li DY; Yang W; Tang GS; Zhang WH; Kuang X; Su W; Han YQ; Chen LM; Xu JH; Liu ZG; Huang J; Zhao CT; Tong HY; Hu JD; Chen CY; Chen XQ; Xiao ZJ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2023 Mar; 44(3):193-201. PubMed ID: 37356980
    [No Abstract]   [Full Text] [Related]  

  • 3. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.
    Boddu P; Masarova L; Verstovsek S; Strati P; Kantarjian H; Cortes J; Estrov Z; Pierce S; Pemmaraju N
    Ann Hematol; 2018 Jan; 97(1):109-121. PubMed ID: 29143068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variables associated with patient-reported outcomes in patients with myeloproliferative neoplasms.
    Shi D; Shi H; Liu X; Duan M; Zhuang J; Du X; Qin L; Hui W; Liang R; Wang M; Chen Y; Li D; Yang W; Tang G; Zhang W; Kuang X; Su W; Han Y; Chen L; Xu J; Liu Z; Huang J; Zhao C; Tong H; Hu J; Chen C; Chen X; Xiao Z; Jiang Q
    Leuk Lymphoma; 2021 Nov; 62(11):2703-2715. PubMed ID: 34098836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey.
    Mesa R; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Boyle J; Mascarenhas JO
    BMC Cancer; 2016 Feb; 16():167. PubMed ID: 26922064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Health-related quality of life and its associated variables in Chinese patients with Philadelphia-negative myeloproliferative neoplasms].
    Bao M; Shi DY; Shi HX; Liu XL; Duan MH; Zhuang JL; Du X; Qin L; Hui WH; Liang R; Wang MF; Chen Y; Li DY; Yang W; Tang GS; Zhang WH; Kuang X; Su W; Han YQ; Chen LM; Xu JH; Liu ZG; Huang J; Zhao CT; Tong HY; Hu JD; Chen CY; Chen XQ; Xiao ZJ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2021 Dec; 42(12):985-992. PubMed ID: 35045668
    [No Abstract]   [Full Text] [Related]  

  • 7. Impact of Myeloproliferative neoplasms on patients' employment status and work productivity in the United States: results from the living with MPNs survey.
    Yu J; Parasuraman S; Paranagama D; Bai A; Naim A; Dubinski D; Mesa R
    BMC Cancer; 2018 Apr; 18(1):420. PubMed ID: 29653557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms.
    Mora B; Passamonti F
    Curr Hematol Malig Rep; 2022 Oct; 17(5):127-139. PubMed ID: 36048275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
    Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
    Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives.
    Baumeister J; Chatain N; Sofias AM; Lammers T; Koschmieder S
    Cells; 2021 Dec; 10(12):. PubMed ID: 34944059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities.
    Coltro G; Loscocco GG; Vannucchi AM
    Int Rev Cell Mol Biol; 2021; 365():1-69. PubMed ID: 34756241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leukocytosis and MPNs: Where do we stand?
    Coltoff A
    Leuk Lymphoma; 2023 Mar; 64(3):564-572. PubMed ID: 36519233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
    Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MERGE: A Multinational, Multicenter Observational Registry for Myeloproliferative Neoplasms in Asia, including Middle East, Turkey, and Algeria.
    Yassin MA; Taher A; Mathews V; Hou HA; Shamsi T; Tuğlular TF; Xiao Z; Kim SJ; Depei W; Li J; Rippin G; Sadek I; Siddiqui A; Wong RS
    Cancer Med; 2020 Jul; 9(13):4512-4526. PubMed ID: 32351024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey.
    Mesa RA; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Naim A; Parasuraman S; Boyle J; Mascarenhas JO
    Cancer; 2017 Feb; 123(3):449-458. PubMed ID: 27690182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey.
    Harrison CN; Koschmieder S; Foltz L; Guglielmelli P; Flindt T; Koehler M; Mathias J; Komatsu N; Boothroyd RN; Spierer A; Perez Ronco J; Taylor-Stokes G; Waller J; Mesa RA
    Ann Hematol; 2017 Oct; 96(10):1653-1665. PubMed ID: 28780729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera.
    Delic S; Rose D; Kern W; Nadarajah N; Haferlach C; Haferlach T; Meggendorfer M
    Br J Haematol; 2016 Nov; 175(3):419-426. PubMed ID: 27447873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease-Specific Derangement of Circulating Endocannabinoids and
    Forte D; Fanelli F; Mezzullo M; Barone M; Corradi G; Auteri G; Bartoletti D; Martello M; Ottaviani E; Terragna C; Curti A; Pagotto U; Palandri F; Cavo M; Catani L
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32403407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.
    Landgren O; Goldin LR; Kristinsson SY; Helgadottir EA; Samuelsson J; Björkholm M
    Blood; 2008 Sep; 112(6):2199-204. PubMed ID: 18451307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.